Suppr超能文献

儿童和青少年费城染色体阳性及费城样急性淋巴细胞白血病:当前治疗、争议与新观念

Philadelphia Chromosome Positive and Philadelphia-Like Acute Lymphoblastic Leukemia in Children and Adolescents: Current Management, Controversies and Emerging Concepts.

作者信息

Ganguly Shuvadeep, Sasi Archana, Pushpam Deepam, Bakhshi Sameer

机构信息

Department of Medical Oncology, Dr. B.R.A. Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, 110029, India.

出版信息

Indian J Pediatr. 2024 Jan;91(1):37-46. doi: 10.1007/s12098-023-04782-8. Epub 2023 Aug 26.

Abstract

Philadelphia chromosome positive (Ph+) acute lymphoblastic lymphoma (ALL) is an uncommon subtype of ALL in children, seen in 2-5% cases. Diagnostic evaluation includes conventional karyotyping and detection of BCR-ABL1 translocation by fluorescence in-situ hybridization (FISH) or reverse transcriptase polymerase chain reaction (RT-PCR). For children, the frontline management includes combination of intensive chemotherapy along with imatinib (300-340 mg/m/d) or dasatinib (60-80 mg/m/d). Imatinib/dasatinib should be introduced in induction as soon as results for BCR-ABL are available. Minimal residual disease (MRD) monitoring is essential; multi-parametric flowcytometry and immunoglobulin/T-cell receptor rearrangement PCR are the preferred methods. Intrathecal therapy with at least 12 doses of methotrexate is adequate for central nervous system (CNS) prophylaxis, but cranial radiation is necessary for CNS3 involvement. Allogeneic hematopoietic stem cell transplantation (HSCT) in first remission may be considered in high-risk cases (persistent MRD positivity/induction failure). Maintenance therapy with tyrosine kinase inhibitors (TKI) in children is debatable, with potential concerns for long term adverse effects. At relapse, the choice of TKI is guided by the presence of BCR-ABL tyrosine kinase domain resistance mutations, although the frequency of resistance mutations in children are lower. Allogeneic HSCT is essential for consolidation in second remission, if not done. Ph-like ALL is a newly recognized molecular entity, with gene expression profile similar to Ph+ALL and poor survival outcomes. In resource-constrained settings, a stepwise cost-effective diagnostic evaluation should be considered among high-risk patients without recurrent genetic abnormalities. Current treatment strategies remain similar to Ph-negative ALL. Enrolment in clinical trials is encouraged for such children to evaluate potential targeted agents in this subtype.

摘要

费城染色体阳性(Ph+)急性淋巴细胞白血病(ALL)是儿童ALL中一种不常见的亚型,占病例的2%-5%。诊断评估包括传统核型分析以及通过荧光原位杂交(FISH)或逆转录聚合酶链反应(RT-PCR)检测BCR-ABL1易位。对于儿童,一线治疗包括强化化疗联合伊马替尼(300-340mg/m²/天)或达沙替尼(60-80mg/m²/天)。一旦获得BCR-ABL结果,应在诱导期尽早引入伊马替尼/达沙替尼。微小残留病(MRD)监测至关重要;多参数流式细胞术和免疫球蛋白/T细胞受体重排PCR是首选方法。鞘内注射至少12剂甲氨蝶呤足以预防中枢神经系统(CNS)受累,但对于CNS3受累则需要进行颅脑放疗。高危病例(持续MRD阳性/诱导失败)在首次缓解期可考虑进行异基因造血干细胞移植(HSCT)。儿童使用酪氨酸激酶抑制剂(TKI)进行维持治疗存在争议,因为可能存在长期不良反应。复发时,TKI的选择取决于BCR-ABL酪氨酸激酶结构域耐药突变的存在,尽管儿童中耐药突变的发生率较低。如果未进行异基因HSCT,对于第二次缓解期的巩固治疗则必不可少。Ph样ALL是一种新认识的分子实体,其基因表达谱与Ph+ALL相似,生存结果较差。在资源有限的环境中,对于没有复发性基因异常的高危患者,应考虑采用逐步具有成本效益的诊断评估。目前的治疗策略与Ph阴性ALL相似。鼓励此类儿童参加临床试验,以评估该亚型中潜在的靶向药物。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验